Skip to main content
Premium Trial:

Request an Annual Quote

Infectious Disease Testing Firm Curative Acquires KorvaLabs

NEW YORK – Infectious disease testing startup Curative announced Tuesday it has acquired CLIA-certified analytical laboratory KorvaLabs for undisclosed terms. 

The two companies had previously partnered in March to manufacture and process Curative's PCR-based SARS-CoV-2 test, which received Emergency Use Authorization from the US Food and Drug Administration in April. The test detects SARS-CoV-2 nucleic acids in oropharyngeal, nasopharyngeal, and nasal swabs, along with oral fluid specimens. The use of oral fluid samples decreases exposure risk for healthcare workers and requires less personal protective equipment than nasopharyngeal swab tests. 

So far, the companies have processed 245,371 tests and have the capacity to provide 14,000 tests per day, Curative said. The Los Angeles-based company was founded this past January to develop tests for sepsis but turned its attention to COVID-19 in the midst of the pandemic.

San Dimas, California-based KorvaLabs' facilities were converted into dedicated spaces for producing and processing Curative's test.

"Curative has worked in close partnership with KorvaLabs for months now, so our decision to move forward with the acquisition just serves to formalize that relationship," Curative Founder and CEO Fred Turner said. "Since day one, our mission has been to produce, distribute, and process as many tests as possible."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.